Anthracycline cardiotoxicity is a nebulous concept. Ever since the late David Karnofsky noted the association between the chronic administration of daunorubicin and the development of cardiac failure, clinicians have been trying to prevent this severe complication. Even though other cytotoxic agents cause major organ impairment such as bleomycin (lung toxicity) and cisplatin (nephrotoxicity), cardiotoxicity has resulted in the generation of more investigation than any other organ toxicity. This is partly due to the importance of the anthracyclines as anticancer drugs which are seminal for the treatment of a number of malignancies including breast cancer, leukaemias, lymphomas and sarcomas, but also for the clues offered in understanding the mechanisms of anticancer drug action and the aetiology of cardiomyopathies.
The most difficult issue in understanding the problem of anthracycline cardiotoxicity is a clear definition of the problem. Von Hoff et al. in two landmark papers documenting its incidence, used clinical cardiac failure as a measure of anthracycline cardiotoxicity in a population of patients receiving either daunorubicin or doxorubicin. The overall incidence of cardiac failure in these retrospective studies was age and dose related and was 7% for a cumulative dose of 550 mg/m 2 of doxorubicin [1] and 1.5% for a cumulative dose of daunorubicin of 600 mg/m 2 [2] . However, as investigations for cardiac impairment have become more sophisticated, the definition of cardiotoxicity has relied upon measures such as a fall in resting left.ventricular ejection fraction, typical changes of anthracycline cardiomyopathy on either biopsy specimens or at autopsy and, even in some cases, changes in cardiac rhythm as measured with an electrocardiograph. In clinical studies such as those in which cardioprotective drugs such as dexrazoxane have been investigated, at least three different parameters have been measured. For example, in the studies of Speyer et al. [3] , cardiotoxicity was defined using falls in left ventricular ejection fraction, the characteristic pathological changes on endomyocardial biopsy and the New York Heart Association clinical criteria for cardiac failure. Using clinical criteria poses problems especially in patients with malignant disease in whom the development of pulmonary crepitations and dyspnoea on exertion may be due to infection, underlying lung pathology or cardiac failure. With the use of more specific and more sensitive criteria, anthracycline cardiac toxicity is more frequently diagnosed [3] but whether this is of clinical importance awaits studies with longer follow-up.
One of the major areas of missing information is the prevalence of underlying subclinical and clinical cardiac impairment in patients with malignant disease who have either never had anthracyclines or in fact may never have even had chemotherapy. Since most patients with malignancy are older, it is of interest to know how these patients fared with regard to the above parameters of cardiotoxicity measured over time with drugs other than the anthracyclines. Information addressing this issue is sparse certainly no long term data on change in resting left ventricular ejection fraction is available.
However, the most crucial current problem is the prevention of a chronic life threatening toxicity for patients with malignant disease. This is of importance especially when these drugs are used in patients with potentially curable cancers where the late effects of doxorubicin are uncertain. This is a particular problem in paediatric malignancies where potentially curative therapy may be compromised by the fear of late toxicity. As a greater number of children are being cured from childhood malignancy, the problem of anthracycline cardiotoxicity has become the foremost medical problem in these survivors. Von Hoff indicated in his initial publication that children are at greater risk for developing anthracycline cardiomyopathy [2] . With careful followup, Lipshultz et al. have demonstrated clinical and/or subclinical cardiotoxicity as measured by abnormalities in left ventricular contractility or wall thickness in 57% of childhood survivors of ALL [4] .
Therefore besides age, the identification of pre-existing risk factors for anthracycline induced cardiotoxicity are essential in avoiding this problem. Those identified include pre-existing cardiac disease such as ischaemic heart disease, hypertensive heart disease [1] , higher rates of administration [7] , radiation therapy to the heart whether delivered concurrently or before or after the use of anthracycline [5, 6] and as well as younger patients, those who are of advanced age [1, 2] . In most clinics now, patients with adverse prognostic factors would have a resting radionuclide ejection fraction, and by excluding patients at risk, cardiac toxicity appears to be diminished.
As indicated earlier, an understanding of the mechanism of anthracycline cardiotoxicity may enable us to develop cytotoxic agents or modify existing agents to be less toxic and more tumour specific. Another benefit may be the ability to understand other organ diseases. For example, the elucidation of free radical mechanisms in the heart caused by anthracycline cardiotoxicity has enabled a greater understanding of the mechanism of ischaemic cardiac damage. A by product of this knowledge may be the development of cardioprotective drugs or even drugs which are effective against myocardial ischaemia. The mechanism of anthracycline cardiotoxicity is not completely understood but it is well known that anthracyclines are powerful inducers of free radical species resulting in the formation of oxygen free radicals [8] . These have been shown to be capable of causing lipid peroxidation with the mitochondrial membranes being especially susceptible. The heart appears to be susceptible to free radical damage because of lower antioxidant levels when compared to other tissues. This is in concordance with the histopathologic changes seen on both light and electron microscopy in the anthracycline damaged heart where mitochondrial damage is one of the earliest features seen [5, 6] .
This mechanism suggested that low peak doses of anthracyclines would avoid cardiotoxicity and this was subsequently confirmed by Legha et al. [7] Further investigation revealed that iron was important to initiate hydroxyl radical formation. This led to the exploration of chelating agents and ultimately the identification of dexrazoxane as a potent cardioprotector possibly by binding intracellular iron [8] .
For almost two decades the most practical method for decreasing cardiotoxicity besides excluding patients at high risk was the delivery of anthracycline to avoid high peak levels of the drug [7] . Therefore, the development of the cardioprotective agent dexrazoxane has been a boon especially in the treatment of young patients and those receiving anthracyclines as curative therapy. The initial trials of cardioprotective agents demonstrated conclusively their ability to substantially decrease cardiotoxicity without effecting response rates [3] . However, of the eight prospective randomised trials, all of which demonstrated substantial cardioprotection, one did demonstrate a lower response rate and shorter time to progression when dexrazoxane was used with doxorubicin [9] . The other trials, however, did not demonstrate this feature [10] . This trial raised the question as to whether the mechanism of cardiotoxicity was identical to that of cytotoxicity and whether abrogating cardiotoxicity would abrogate the effect of anthracyclines on tumours. Whether an antagonistic effect on cytotoxicity is a true finding or a chance finding in these trials is unclear but does encourage some caution in the use of cardioprotectors. However, for children and adults in whom cardiotoxicity is believed to be a major potential problem, the use of a cardioprotector may be indicated [10] .
Possibly the most encouraging new development in the abrogation of anthracycline cardiotoxicity is the development of liposomal doxorubicin. This product has already been approved in many countries for use in patients with epidemic Kaposis' sarcoma. However, one must be cautious in assuming that liposomal doxorubicin is a less toxic form of doxorubicin. This product will need to be evaluated as a new agent as it may have a totally different spectrum of toxicity and activity. The paper by Martin et al. in this issue of Annals of Oncology addresses the potential cardiotoxicity of liposomal doxorubicin. The authors have carefully investigated 10 patients with Kaposis' sarcoma who had received cumulative doses of pegylated liposomal doxorubicin administered at a dose of 20 mg/m 2 bi-weekly. In a retrospective study, they have compared the data for these 10 patients to two control groups. Their use of endomyocardial biopsy which is acknowledged as the most specific and sensitive method for measuring doxorubicin cardiotoxicity suggested less cardiotoxicity with pegylated liposomal doxorubicin. However, one must interpret this paper cautiously and not as definitive evidence of less cardiotoxicity. The data may give us insight into the possible effect of liposomal doxorubicin on the heart but, in essence, only allow us to draw hypotheses which should be tested in prospective randomised trials. The authors acknowledge these weaknesses in their retrospective methodology and cautiously indicate that less severe cardiac changes were seen in patients given liposomal doxorubicin compared to historical control patients administered comparable cumulative doses of doxorubicin. Hopefully these findings will be replicated in prospective randomised studies using not only endomyocardial biopsy as a parameter of doxorubicin cardiotoxicity, but also more conventional parameters such as changes in resting left ventricular ejection fraction and the development of clinical heart failure. The abrogation of anthracycline-induced cardiotoxicity will have enormous implications on the treatment of patients with malignancy especially in those patients who may require retreatment at a future date, those who may require concurrent radiation therapy to the heart, those receiving high doses of anthracyclines in dose intensive therapy and those at either end of the spectrum such as young children and older patients.
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